Golembiewski Elizabeth H, Garcia Bautista Andrea E, Polley Eric, Umpierrez Guillermo E, Galindo Rodolfo J, Brito Juan P, Montori Victor M, Gockerman Janet P, Tesulov Michael, Labatte Bertina, Mickelson Mindy M, McCoy Rozalina G
Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
Department of Public Health Sciences, University of Chicago, Chicago, IL.
Clin Diabetes. 2024 Summer;42(3):371-387. doi: 10.2337/cd23-0042. Epub 2024 Jan 22.
This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).
这项混合方法研究旨在确定在美国两个医疗保健系统接受治疗的40名未使用胰岛素治疗的2型糖尿病成年人的药物治疗偏好。参与者根据相对重要性对各种健康结果和药物属性进行排序,然后将他们的排序置于具体情境中。大多数参与者将失明(63%)、死亡(60%)、心脏病发作(48%)和心力衰竭(48%)列为最重要的健康结果,将降糖效果(68%)列为最重要的药物属性,其次是口服给药(45%)和无胃肠道副作用(38%)。